MPM ASSET MANAGEMENT LLC - Q4 2016 holdings

$212 Million is the total value of MPM ASSET MANAGEMENT LLC's 8 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 0.0% .

 Value Shares↓ Weighting
RDUS  Radius Health, Inc.$147,842,000
-29.7%
3,887,5020.0%69.78%
+1.3%
EPZM  EpiZyme, Inc.$20,929,000
+23.0%
1,729,6740.0%9.88%
+77.2%
SNDX  Syndax Pharmaceuticals, Inc.$15,550,000
-52.7%
2,168,6910.0%7.34%
-31.8%
CHMA  Chiasma, Inc.$11,186,000
-33.7%
5,736,2960.0%5.28%
-4.4%
ELGX  Endologix, Inc.$6,415,000
-55.3%
1,121,4470.0%3.03%
-35.6%
CNAT  Conatus Pharmaceuticals, Inc.$6,282,000
+163.5%
1,192,0800.0%2.96%
+279.6%
PRTO  Proteon Therapeutics, Inc.$1,868,000
-79.6%
983,3810.0%0.88%
-70.6%
PETX  Aratana Therapeutics Inc.$1,795,000
-23.3%
250,0000.0%0.85%
+10.6%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2017-02-07
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Chiasma, Inc.24Q2 202119.8%
Aratana Therapeutics, Inc.24Q1 201926.8%
Conatus Pharmaceuticals, Inc.23Q1 20199.7%
Rhythm Pharmaceuticals, Inc.19Q2 202269.9%
Harpoon Therapeutics, Inc.19Q3 202331.9%
Syndax Pharmaceuticals, Inc.19Q3 202014.5%
Radius Health, Inc.17Q2 201876.4%
TCR2 Therapeutics, Inc.17Q1 202329.1%
Proteon Therapeutics, Inc.17Q4 20183.0%
EpiZyme, Inc.15Q4 201635.9%

View MPM ASSET MANAGEMENT LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-13
13F-HR2023-11-14
13F-HR/A2023-09-07
13F-HR2023-08-14
42023-06-05
42023-05-24
13F-HR2023-05-12
13F-HR2023-02-14
13F-HR2022-11-14
13F-HR2022-08-11

View MPM ASSET MANAGEMENT LLC's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported total value is incorrect (211866000.0 != 211867000.0)

Export MPM ASSET MANAGEMENT LLC's holdings